[Bleomycin: cellular and vascular alteration in a patient (author's transl)].
D000368:Aged; D001761:Bleomycin / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D001808:Blood Vessels / Q000187:drug effects; D002280:Basal Cell Carcinoma / Q000188:drug therapy / Q000473:pathology*; D002463:Cell Membrane Permeability / Q000187:drug effects; D002467:Cell Nucleus; D002477:Cells / Q000378:metabolism; D002843:Chromatin / Q000378:metabolism; D004273:DNA, Neoplasm; D004727:Endothelium / Q000187:drug effects; D004847:Epithelial Cells; D004848:Epithelium / Q000187:drug effects; D005260:Female; D006651:Histocytochemistry; D006801:Humans; D002479:Inclusion Bodies; D007269:Injections, Intra-Arterial; D012878:Skin Neoplasms / Q000188:drug therapy / Q000473:pathology*
D002843:Chromatin; D004273:DNA, Neoplasm; D001761:Bleomycin
Bleomycin: Tumorzellveränderungen und Geffässwirkungen beim Patienten